Osimertinib in pulmonary manifestations: Two case reports and review of the literature

Hannah Lu, Jonathan Dowell

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Osimertinib is an oral, irreversible epidermal growth factor receptor inhibitor that is associated with various pulmonary manifestations including transient asymptomatic pulmonary opacities (TAPOs) and pneumonitis. We present a case of a 61-year-old female with Stage IV lung adenocarcinoma, who developed bilateral ground glass opacities on her chest-computed tomography (CT) three months after initiating osimertinib. Her imaging findings were thought to represent lymphangitic carcinomatosis responding to chemotherapy rather than drug induced toxicity, and she was continued on osimertinib. Conversely, we present a second case of a 57-year-old female with Stage IV lung adenocarcinoma who developed osimertinib-induced pneumonitis and was successfully rechallenged with osimertinib and glucocorticoids. These cases, described herein, illustrate examples of the range of pulmonary manifestations of osimertinib, as well as the safety of rechallenging patients with osimertinib and glucocorticoids following the development of pneumonitis.

Original languageEnglish (US)
Pages (from-to)315-319
Number of pages5
JournalIn Vivo
Issue number1
StatePublished - 2020
Externally publishedYes


  • Disease response
  • Ground-glass opacities
  • Osimertinib
  • Pneumonitis
  • Rechallenge
  • Review

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology


Dive into the research topics of 'Osimertinib in pulmonary manifestations: Two case reports and review of the literature'. Together they form a unique fingerprint.

Cite this